James G Christensen Selected Research

James G Christensen Research Topics

Disease

92	Neoplasms (Cancer) 04/2024 - 01/2003
21	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 04/2024 - 02/2005
9	Lung Neoplasms (Lung Cancer) 02/2024 - 05/2008
9	Neoplasm Metastasis (Metastasis) 10/2023 - 03/2009
6	Colorectal Neoplasms (Colorectal Cancer) 04/2024 - 02/2011
5	Adenocarcinoma 02/2024 - 02/2005
5	Breast Neoplasms (Breast Cancer) 01/2018 - 03/2009
5	Glioblastoma (Glioblastoma Multiforme) 04/2012 - 06/2005
5	Stomach Neoplasms (Stomach Cancer) 03/2012 - 02/2006
4	Carcinoma (Carcinomatosis) 01/2019 - 06/2005
4	Neuroblastoma 11/2011 - 05/2008
3	Fatigue 02/2024 - 04/2013
3	Diarrhea 02/2024 - 04/2013
3	Colonic Neoplasms (Colon Cancer) 01/2020 - 07/2011
3	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 03/2012 - 12/2007
2	Nausea 02/2024 - 01/2023
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 02/2024 - 06/2005
2	Triple Negative Breast Neoplasms 01/2018 - 03/2013
2	Melanoma (Melanoma, Malignant) 07/2014 - 03/2009
2	Ovarian Neoplasms (Ovarian Cancer) 12/2013 - 01/2010
2	Retinoblastoma (Glioblastoma, Retinal) 08/2013 - 03/2012
2	Renal Cell Carcinoma (Grawitz Tumor) 08/2013 - 05/2006
2	Adenocarcinoma of Lung 06/2013 - 08/2012
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 06/2013 - 03/2012
2	Disease Progression 04/2013 - 05/2006
2	Genetic Translocation (Chromosomal Translocation) 05/2008 - 12/2007
2	Lymphoma (Lymphomas) 04/2008 - 12/2007
1	Vomiting 01/2023

Drug/Important Bio-Agent (IBA)

26	CrizotinibIBA 01/2020 - 05/2007
23	Phosphotransferases (Kinase)IBA 01/2015 - 09/2003
14	Proteins (Proteins, Gene)FDA Link 04/2024 - 07/2005
13	adagrasibIBA 04/2024 - 01/2020
12	Tyrosine Kinase InhibitorsIBA 01/2019 - 10/2004
12	Sunitinib (Sutent)FDA Link 06/2013 - 01/2003
11	Anaplastic Lymphoma KinaseIBA 01/2015 - 12/2007
11	Proto-Oncogene Proteins c-metIBA 07/2012 - 09/2003
10	Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA 06/2013 - 11/2003
9	Biomarkers (Surrogate Marker)IBA 02/2024 - 06/2005
9	ErbB Receptors (EGF Receptor)IBA 10/2012 - 06/2005
9	5- ((2,6- dichlorobenzyl)sulfonyl)- 3- ((3,5- dimethyl- 4- ((2- (pyrrolidin- 1- ylmethyl)pyrrolidin- 1- yl)carbonyl)- 1H- pyrrol- 2- yl)methylene)- 1,3- dihydro- 2H- indol- 2- oneIBA 02/2011 - 11/2003
6	LigandsIBA 01/2022 - 11/2003
6	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 11/2014 - 07/2005
6	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 11/2011 - 09/2003
4	2- amino- 8- (4- (2- hydroxyethoxy)cyclohexyl)- 6- (6- methoxypyridin- 3- yl)- 4- methylpyrido(2,3- d)pyrimidin- 7(8H)- oneIBA 11/2014 - 11/2011
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2013 - 11/2008
4	2- (4- (3- quinolin- 6- ylmethyl- 3H- (1,2,3)triazolo(4,5- b)pyrazin- 5- yl)pyrazol- 1- yl)ethanolIBA 06/2013 - 01/2012
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/2013 - 06/2005
3	Alanine Transaminase (SGPT)IBA 02/2024 - 01/2020
3	glesatinibIBA 02/2024 - 11/2017
3	Pemetrexed (MTA)FDA Link 11/2023 - 10/2022
3	KRASG12D inhibitor MRTX1133IBA 01/2023 - 01/2022
3	Tyrosine (L-Tyrosine)FDA Link 01/2018 - 06/2005
3	dacomitinibIBA 11/2014 - 02/2012
3	Docetaxel (Taxotere)FDA Link 03/2013 - 07/2009
3	Lapatinib (GW572016)FDA Link 09/2012 - 02/2012
3	Trastuzumab (Herceptin)FDA Link 09/2012 - 07/2005
3	Angiogenesis InhibitorsIBA 07/2012 - 10/2007
3	tyrosine receptor (receptor, tyrosine)IBA 04/2012 - 05/2006
3	Gefitinib (Iressa)FDA Link 02/2012 - 07/2005
3	((3Z)- N- (3- chlorophenyl)- 3- ((3,5- dimethyl- 4- ((4- methylpiperazin- 1- yl)carbonyl)- 1H- pyrrol- 2- yl)methylene)- N- methyl- 2- oxo- 2,3- dihydro- 1H- indole- 5- sulfonamide)IBA 04/2009 - 09/2003
2	SuspensionsIBA 02/2024 - 01/2023
2	TabletsIBA 02/2024 - 01/2023
2	Capsules (Microcapsules)IBA 02/2024 - 01/2023
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 02/2024 - 01/2023
2	sotorasibIBA 02/2024 - 01/2021
2	Cetuximab (Erbitux)FDA Link 01/2023 - 02/2011
2	SaltsIBA 01/2023 - 06/2005
2	PlatinumIBA 01/2022 - 12/2013
2	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2021 - 06/2013
2	Codon (Codons)IBA 01/2021 - 06/2013
2	Histone Deacetylases (Histone Deacetylase)IBA 01/2019 - 01/2018
2	mocetinostatIBA 01/2019 - 01/2018
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 10/2016 - 11/2011
2	Sirolimus (Rapamycin)FDA Link 11/2014 - 03/2005
2	palbociclibIBA 07/2014 - 08/2013
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 12/2013 - 02/2012
2	Insulin-Like PeptidesIBA 12/2013 - 03/2012
2	figitumumabIBA 12/2013 - 07/2011
2	mirdametinibIBA 12/2013 - 08/2012
2	nirogacestatIBA 03/2013 - 09/2012
2	Amyloid Precursor Protein Secretases (beta-Secretase)IBA 03/2013 - 09/2012
2	AfatinibIBA 10/2012 - 02/2012
2	Messenger RNA (mRNA)IBA 09/2012 - 06/2005
2	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 04/2012 - 04/2012
2	Small Interfering RNA (siRNA)IBA 04/2012 - 02/2005
2	N- (2- (6- (4- cyclobutylamino- 5- trifluoromethylpyrimidine- 2- ylamino)- 1,2,3,4- tetrahydro- 1,4- epiazano- naphthalen- 9- yl)- 2- oxo- ethyl)acetamideIBA 03/2012 - 04/2010
2	Canertinib (CI 1033)IBA 02/2012 - 06/2005
2	Phosphatidylinositols (Phosphatidylinositol)IBA 11/2011 - 11/2008
2	Adenosine Triphosphate (ATP)IBA 08/2011 - 11/2003
2	Semaphorins (Semaphorin)IBA 04/2009 - 02/2005
2	Growth Factor ReceptorsIBA 11/2008 - 02/2006
2	Mesylates (Mesylate)IBA 05/2006 - 06/2005
2	Imatinib Mesylate (Gleevec)FDA Link 05/2006 - 07/2005
1	NucleotidesIBA 04/2024
1	SOS1 ProteinIBA 04/2024
1	Protein-Arginine N-Methyltransferases (Methyltransferase, Protein Arginine)IBA 11/2023
1	glycolic acid (glycolate)IBA 01/2023

Therapy/Procedure

41	Therapeutics 04/2024 - 01/2003
4	Oral Administration 10/2022 - 06/2005
4	Drug Therapy (Chemotherapy) 01/2022 - 02/2012